News coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.1030885474393 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) opened at $3.92 on Monday. Catalyst Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.51. The stock has a market capitalization of $401.70, a price-to-earnings ratio of -18.67 and a beta of 1.68.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. equities research analysts anticipate that Catalyst Pharmaceuticals will post -0.22 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://baseballnewssource.com/markets/catalyst-pharmaceuticals-cprx-getting-somewhat-positive-press-coverage-report-shows/1814067.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with our FREE daily email newsletter.